Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, resulting in vasodilation and reduced systemic vascular resistance.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Short-term treatment of hypertension when oral therapy is not feasible or desirable,Management of hypertensive emergencies,Postoperative hypertension
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Intravenous infusion: Initial rate 5 mg/hour, titrate by 2.5 mg/hour every 5-15 minutes to a maximum of 15 mg/hour. For hypertension, typical maintenance 3-5 mg/hour.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Terminal elimination half-life is 8.6 hours (range 6–10 hours). In patients with hepatic impairment, half-life may be prolonged up to 14 hours. No significant change in renal impairment.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Metabolites are excreted renally and fecally. Fecal excretion accounts for approximately 35% of total elimination.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
>95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Low protein binding; 0–11% bound, primarily to albumin.
Vd is approximately 0.4 L/kg in healthy subjects, indicating moderate tissue distribution. Increased Vd in patients with hepatic cirrhosis (up to 1.0 L/kg).
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Oral bioavailability is approximately 35% due to extensive first-pass hepatic metabolism. Intravenous bioavailability is 100%.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
No specific GFR-based dose adjustment required; use with caution in severe renal impairment (Cr Cl <30 m L/min) and monitor closely.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
Child-Pugh Class A: Reduce initial dose to 2.5 mg/hour; titrate cautiously. Class B or C: Avoid use or use very low doses under close monitoring.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Not FDA-approved for pediatric use. Limited data: Continuous infusion 0.5-5 mcg/kg/min, titrate to effect. Initiate at 0.5-1 mcg/kg/min.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Elderly patients: Initiate at lower infusion rates (e.g., 2.5 mg/hour) and titrate slowly due to increased sensitivity and higher risk of hypotension.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
None.
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
May cause hypotension, especially in patients with compromised cardiac function,Use with caution in patients with hepatic impairment or reduced hepatic blood flow,May exacerbate angina in patients with obstructive coronary artery disease,Monitor blood pressure, heart rate, and ECG continuously during infusion,Risk of peripheral edema, headache, and reflex tachycardia
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Known hypersensitivity to nicardipine or any component of the formulation,Patients with severe aortic stenosis (may reduce coronary perfusion pressure),Patients with advanced aortic stenosis (may precipitate left ventricular failure)
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
NO FOOD INTERACTIONS DUE TO INTRAVENOUS ROUTE. HOWEVER, GRAPEFRUIT JUICE MAY INCREASE SYSTEMIC EXPOSURE IF TAKEN ORALLY; IV ADMINISTRATION NOT AFFECTED.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
First trimester: Limited data; no clear evidence of major malformations in humans, but animal studies show fetotoxicity at high doses. Second/third trimester: Potential fetal hypoxia due to maternal hypotension; consider risk-benefit.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Excreted in breast milk in small amounts (M/P ratio unknown); use with caution, monitor infant for hypotension.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Dose may require adjustment due to increased volume of distribution and clearance; start with lower doses and titrate to effect.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
NICARDIPINE IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER WITH HIGH VASCULAR SELECTIVITY. INTRAVENOUS ADMINISTRATION ALLOWS PRECISE TITRATION FOR HYPERTENSIVE URGENCY OR EMERGENCY. IT IS METABOLIZED BY CYP3A4; CAUTION WITH STRONG INHIBITORS/INDUCERS. CONTINUOUS BLOOD PRESSURE MONITORING REQUIRED. MAY CAUSE REFLEX TACHYCARDIA. AVOID IN ADVANCED AORTIC STENOSIS. SOLUTION IS LIGHT-SENSITIVE; PROTECT FROM LIGHT DURING INFUSION. TITRATE TO TARGET BP; ONSET ~5 MIN, DURATION 3-4 HOURS.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
This medication is given intravenously to quickly lower your blood pressure.,Your blood pressure will be monitored continuously during infusion.,Report any symptoms of dizziness, headache, or ankle swelling.,Do not stop the medication abruptly; it is administered by healthcare professionals.,Inform your healthcare provider if you have liver disease or aortic stenosis.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Ximelagatran, a prodrug of the direct thrombin inhibitor melagatran, is primarily metabolized by CYP450 enzymes, particularly CYP2C9 and to a lesser extent CYP3A4. Nicardipine, a dihydropyridine calcium channel blocker, is extensively metabolized by CYP3A4. Coadministration of ximelagatran with nicardipine may result in inhibition of CYP3A4-mediated metabolism of nicardipine, leading to increased nicardipine plasma concentrations, enhanced hypotensive effects, and potentially elevated risk of adverse events such as edema, headache, and dizziness."
"Cinnarizine, a piperazine derivative with antihistaminic and calcium channel-blocking properties, inhibits cytochrome P450 (CYP) 3A4, the primary enzyme responsible for the metabolism of nicardipine, a dihydropyridine calcium channel blocker. This inhibition leads to reduced clearance and elevated plasma concentrations of nicardipine, potentially resulting in enhanced vasodilation, hypotension, reflex tachycardia, and increased risk of adverse effects such as peripheral edema, dizziness, and headache. Clinically, patients may experience exaggerated hypotensive responses and cardiovascular instability."
"Etoricoxib, a selective COX-2 inhibitor, can inhibit the metabolism of nicardipine, a dihydropyridine calcium channel blocker, via competitive inhibition of CYP3A4. This results in elevated plasma concentrations of nicardipine, potentially leading to enhanced hypotensive effects and an increased risk of adverse events such as dizziness, headache, peripheral edema, and reflex tachycardia. Clinically, this interaction may necessitate dose adjustment and careful monitoring of blood pressure and heart rate."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE is a Electrolyte that works by Nicardipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, resulting in vasodilation and reduced systemic vascular resistance.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE is: Intravenous infusion: Initial rate 5 mg/hour, titrate by 2.5 mg/hour every 5-15 minutes to a maximum of 15 mg/hour. For hypertension, typical maintenance 3-5 mg/hour.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE is classified as Category A/B. First trimester: Limited data; no clear evidence of major malformations in humans, but animal studies show fetotoxicity at high doses. Second/third trimester: Potential fetal hypox. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.